Two new guidance documents, the first in a series to published by the MHRA, outline considerations when planning a randomised clinical trial using real-world data.
The need of the hour is to reach patients faster. By reducing both the drug development timeline and the overall cost of pharma research and development we can achieve just that. COVID-19 has been a good example of just what can be achieved.
The U.S. Food and Drug Administration (FDA) is announcing a funding opportunity for projects to support the agency’s understanding of the potential use of real-world data (RWD) to generate real-world evidence (RWE).